Phase 3 Readout

MDWD: Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf

Name: Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf
Start: 2027-03-01
End: 2027-03-01

March 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: March 1, 2027
Company: MediWound Ltd. (MDWD)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Perf

March 1, 2027

MDWD overview →

Company: MediWound Ltd. (MDWD)
Indication: Venous Leg Ulcer (VLU)